Celsion Corporation 10-Q Summary
Business Context and Reporting Period
This is a Quarterly Report (Form 10-Q) for Celsion Corporation for the three-month period ended December 31, 1999. Celsion is a clinical-stage biotechnology company focused on developing thermotherapy systems for cancer treatment. The company has not yet generated product revenue and relies on equity financing to fund research, development, and clinical trials.
Key Financial Metrics
| Metric | Three Months Ended Dec 31, 1999 | Three Months Ended Dec 31, 1998 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(834,663) | $(547,993) |
| Loss Per Share (Basic) | $(0.016) | $(0.014) |
| Operating Cash Flow | $(1,183,297) | $(307,226) |
| Cash and Equivalents (Ending) | $766,989 | $100,114 |
| Working Capital | $682,775 | Not reported for 1998 |
| Accumulated Deficit | $(22,734,865) | Not reported for 1998 |
Material Changes vs. Prior Period
- Net Loss Increase: The net loss increased by approximately 52% to $834,663 from $547,993 in the prior year quarter.
- Operating Expenses: Total operating expenses rose to $842,043 from $524,679.
- Research & Development (R&D): Increased 113% to $355,578. This was driven primarily by a $149,428 non-cash charge for stock issued to Duke University for a technology license and $36,298 in cash for Phase I breast cancer trials.
- Selling, General & Administrative (SG&A): Increased 36% to $486,465. Increases included $75,000 in stock-based compensation for the CEO and $60,000 in stock issued to consultants.
- Cash Position: Cash and cash equivalents decreased by $590,475 during the quarter, primarily due to operating losses and prepaid expense increases, partially offset by $608,466 in proceeds from stock issuances.
Outlook, Risks, and Management Commentary
- Revenue Outlook: The company expects no product revenue until new technologies are developed, clinically tested, and approved by regulatory agencies.
- Capital Needs: Celsion projects total expenditures of approximately $4 million for fiscal year 2000 to fund clinical trials and overhead. Management expects to meet these needs through private placements.
- Recent Financing: A private placement offering consummated on January 31, 2000, netted the company approximately $4.2 million.
- Risks: The company has a significant accumulated deficit and no committed sources of additional financing. If funding is not available, operations may be delayed or scaled back. Future profitability depends on successful clinical trials and regulatory approvals.
- Warrant Redemption: On February 7, 2000, the company called for the redemption of Series 700 and Series 800 Warrants, anticipating substantial exercise due to the low redemption price ($0.01 per share).
Investor Verification Checklist
- Verify the status and results of the Phase I breast cancer trials and BPH clinical trials mentioned in the R&D section.
- Confirm the utilization of the $4.2 million raised in the January 2000 private placement against the projected $4 million fiscal year 2000 budget.
- Monitor the exercise rate of the Series 700 and Series 800 Warrants following the February 2000 redemption call.
- Assess the timeline for regulatory approvals required before any product revenue can be recognized.
- Review the terms of the Duke University license agreement to understand future royalty or milestone obligations.